INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER

Show other versions (1)

The paper considers the state-of-the-art of BCG vaccine treatment for non-muscle invasive bladder cancer. It gives data on the meta-analyses of foreign studies of the efficiency of BCG therapy in this pathology.

Bibliographic Details
Main Author:	K. M. Figurin
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Onkourologiâ
Subjects:	non-muscle invasive bladder cancer vaccine intravesical bcg thera efficiency adverse events
Online Access:	https://oncourology.abvpress.ru/oncur/article/view/74

Similar Items

INTRAVESICAL BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: K. M. Figurin
Published: (2014-07-01)

Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience
by: Vivek Sharma, et al.
Published: (2020-12-01)

Protective role of intravesical BCG in COVID-19 severity
by: Héctor Gallegos, et al.
Published: (2021-03-01)

Prospects for the use of the method of intravesical hyperthermic chemotherapy in the treatment of patients with non-muscle invasive bladder cancer
by: Roman Chystiakov
Published: (2021-04-01)

Adjuvant intravesical chemotherapy with titanium glycerosolvate aquacomplex versus BCG therapy in patients with high risk nonmuscle-invasive bladder cancer
by: A. V. Zamyatin, et al.
Published: (2020-11-01)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
by: Sima P Porten, et al.
Published: (2015-01-01)

Reiter’s syndrome occurred following intravesical BCG immunotherapy: Case presentation
by: Fatih Elbir, et al.
Published: (2015-06-01)

NONMUSCLE INVASIVE TRANSITIONAL CELL CARCINOMA OF URINARY BLADDER – ADJUVANT INTRAVESICAL THERAPIES AFTER TRANSURETHRAL TUMOR RESECTION
by: Nicolae Grigore, et al.
Published: (2017-09-01)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01)

Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01)

COMPARATIVE ANALYSIS OF THE THERAPEUTIC EFFICACY OF PROSPIDINE AND CISPLATIN IN NEOADJUVANT INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: T. I. Shabunina, et al.
Published: (2014-07-01)

COMPARATIVE ANALYSIS OF THE THERAPEUTIC EFFICACY OF PROSPIDINE AND CISPLATIN IN NEOADJUVANT INTRAVESICAL CHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
by: T. I. Shabunina, et al.
Published: (2014-07-01)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
by: Vincenzo Serretta, et al.
Published: (2015-01-01)

Delayed cystectomy for T 1 G 3 TCC of urinary bladder managed initially by TURBT & intravesical immunotherapy (BCG + interferon) rationale & our result
by: N K Mohanty, et al.
Published: (2004-01-01)

Long-term results of adjuvant intravesical chemotherapy with titanium glycerosolvate aquacomplex in patients with high risk nonmuscle-invasive bladder cancer
by: A. V. Zamyatin, et al.
Published: (2019-04-01)

Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study
by: Makito Miyake, et al.
Published: (2021-03-01)

The Management of Non-Invasive Bladder Tumours with Doxorubicin Intravesical Instillation after Transurethral Resection
by: Musa I Al-Gallab, et al.
Published: (2009-04-01)

MAINTENANCE INTRAVESICULAR THERAPY WITH BCG VACCINE AS A STANDARD FOR THE PREVENTION AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN MODERATE AND HIGH RISK GROUPS
by: B. Ya. Alekseev, et al.
Published: (2014-08-01)

MAINTENANCE INTRAVESICULAR THERAPY WITH BCG VACCINE AS A STANDARD FOR THE PREVENTION AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN MODERATE AND HIGH RISK GROUPS
by: B. Ya. Alekseev, et al.
Published: (2014-08-01)

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis
by: Kang Liu, et al.
Published: (2020-02-01)

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer: Abridged summary of the Cochrane Review
by: Stefanie Schmidt, et al.
Published: (2020-07-01)

Economic impacts of the Bacillus Calmette-Guérin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia
by: Mishari H M Alshyarba, et al.
Published: (2020-01-01)

TREATMENT IN PATIENTS WITH MUSCLE NONINVASIVE CARCINOMA OF THE URINARY BLADDER AFTER UNSUCCESSFUL INTRAVESICULAR BCG THERAPY
by: K. M. Figurin
Published: (2014-07-01)

TREATMENT IN PATIENTS WITH MUSCLE NONINVASIVE CARCINOMA OF THE URINARY BLADDER AFTER UNSUCCESSFUL INTRAVESICULAR BCG THERAPY
by: K. M. Figurin
Published: (2014-07-01)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
by: Azharuddin Mohammed, et al.
Published: (2017-12-01)

Intravesical therapy for urothelial carcinoma of the bladder
by: M Manoharan
Published: (2011-01-01)

A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy
by: Seon-Kyu Kim, et al.
Published: (2021-02-01)

Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer
by: Wojciech Krajewski, et al.
Published: (2014-03-01)

Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer
by: Wojciech Krajewski, et al.
Published: (2014-03-01)

Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis
by: Chunliang Cheng, et al.
Published: (2021-09-01)

Nucleotide Oligomerization Domain-like receptor 4 (NLR4) Gene Expression and Interleukin 1-β (IL 1-β) Level in Urine Samples Before and After Intravesical BCG Therapy For Treatment of Bladder Cancer
by: Ahmed Samar Abd Elmoaty Eissa, et al.
Published: (2021-01-01)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
by: Sahyun Pak, et al.
Published: (2021-04-01)

Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
by: Zongren Wang, et al.
Published: (2018-11-01)

What have we learned after 30 years of BCG intravesical therapy for superficial bladder cancer?
by: Marcos Tobias-Machado, et al.
Published: (2009-12-01)

MicroRNA Expression Profile Identifies High Grade, Non-Muscle-Invasive Bladder Tumors at Elevated Risk to Progress to an Invasive Phenotype
by: Sara M. Lenherr, et al.
Published: (2017-02-01)

Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer
by: Sawazaki H, et al.
Published: (2021-08-01)

The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis
by: Ye Z, et al.
Published: (2018-08-01)

LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS
by: M. M. Zorina, et al.
Published: (2016-10-01)

Pyuria as a Predictive Marker of Bacillus Calmette–Guérin Unresponsiveness in Non-Muscle Invasive Bladder Cancer
by: Jungyo Suh, et al.
Published: (2021-08-01)

Miliary tuberculosis following intravesical Bacillus Calmette and Guérin therapy: A rare complication of a frequent procedure
by: Lobna Loued, et al.
Published: (2021-09-01)

Cannot write session to /tmp/vufind_sessions/sess_ma4pmr3bnnva6ti70hrcf4nln5